SUPRIYA is guiding for delivering a revenue of Rs 1,000 cr by FY27. The revenue CAGR of 20%+ for FY23-27 could provide opportunity for the stock.
Supriya Lifescience: PAT growth of 27% & Revenue growth of 24% in H1-24 at PE of 24
Supriya Lifescience: PAT growth of 27% …
Supriya Lifescience: PAT growth of 27% & Revenue growth of 24% in H1-24 at PE of 24
SUPRIYA is guiding for delivering a revenue of Rs 1,000 cr by FY27. The revenue CAGR of 20%+ for FY23-27 could provide opportunity for the stock.